PIK3CA mutations in mucinous cystic neoplasms of the pancreas

scientific article

PIK3CA mutations in mucinous cystic neoplasms of the pancreas is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/MPA.0000000000000034
P932PMC publication ID4109032
P698PubMed publication ID24518503

P50authorRalph H. HrubanQ21063634
P2093author name stringGloria H Su
Wanglong Qiu
Dario Garcia-Carracedo
Zong-Ming Chen
Sophia M Tang
Alicia S Huang
P2860cites workMutations of PIK3CA in gastric adenocarcinomaQ21261219
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusQ24600932
Core signaling pathways in human pancreatic cancers revealed by global genomic analysesQ24606006
A transforming mutation in the pleckstrin homology domain of AKT1 in cancerQ27646556
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicQ27824826
High frequency of mutations of the PIK3CA gene in human cancersQ28131776
The biology and clinical relevance of the PTEN tumor suppressor pathwayQ28272157
The phosphatidylinositol 3-Kinase AKT pathway in human cancerQ29547860
Absence of AKT1 mutations in glioblastomaQ30439629
Mucinous cystic neoplasms of the pancreasQ33865956
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancersQ33987852
Cancer-specific mutations in PIK3CA are oncogenic in vivoQ34335169
Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatmentQ34620062
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreasQ35606891
Clinical importance of precursor lesions in the pancreasQ36829541
Cystic neoplasia of the pancreas: pathology and biologyQ36980389
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceQ37036297
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancerQ37474182
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.Q37558625
Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinomaQ38445188
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinomaQ40218014
PIK3CA mutations in head and neck squamous cell carcinomaQ40305620
Mutation of the PIK3CA gene in anaplastic thyroid cancer.Q40351486
Mutant PIK3CA promotes cell growth and invasion of human cancer cellsQ40410776
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancersQ40442452
Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion.Q40462546
PIK3CA mutations in advanced ovarian carcinomasQ43723490
PIK3CA is implicated as an oncogene in ovarian cancer.Q46015944
PIK3CA mutations in nasopharyngeal carcinoma.Q53355100
Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.Q53417898
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.Q53629192
Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas.Q54672534
Tumor-suppressing pathways in cystic pancreatic tumors.Q54798453
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and MedulloblastomasQ57293479
K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas.Q64937598
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomasQ72016451
p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancyQ73045964
Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancyQ73086227
Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progressionQ73183545
Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms?Q73448078
Oncogenic mutations of PIK3CA in human cancersQ80826963
Mutation of the PIK3CA gene in ovarian and breast cancerQ80945762
P433issue2
P921main subjectpancreasQ9618
P304page(s)245-249
P577publication date2014-03-01
P1433published inPancreasQ15762014
P1476titlePIK3CA mutations in mucinous cystic neoplasms of the pancreas
P478volume43

Reverse relations

cites work (P2860)
Q28082890A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas
Q93001657Advanced diagnostics for pancreatic cysts: Confocal endomicroscopy and molecular analysis
Q49629569Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts
Q39238536DNA testing of pancreatic cyst fluid: is it ready for prime time?
Q90135274Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines
Q30234478Insights into the Pathogenesis of Pancreatic Cystic Neoplasms
Q89918641Molecular markers contribute to the clinical diagnosis for pancreatic cystic neoplasms
Q48344381Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression.
Q48310994Mucinous cystic neoplasms of the pancreas: high-resolution cross-sectional imaging features with clinico-pathologic correlation.
Q38757526Novel Biomarkers for Pancreatic Cysts
Q26799446Pancreatic adenocarcinoma pathology: changing "landscape"
Q89125881Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia
Q53622486[Classification and malignant potential of pancreatic cystic tumors].

Search more.